Effect of Sitagliptin on Insulin Resistance and Myocardial Metabolism in Heart Failure

This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication. This study will also investigate the effect of sitagliptin on the body's use of sugar, and of the effect of sitagliptin on blood flow to the heart.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : Sitagliptin

Phase: Phase 0

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

1. Diagnosis of nonischemic dilated cardiomyopathy, current NYHA class I-III congestive heart failure 2. Treatment with a stable comprehensive heart failure regimen for at least 3 months (including beta-blockers and ACE-inhibitors or angiotensin receptor blockers unless intolerant) 3. Age > 18 yrs

External Links

Explore related trials

Contact information

Primary Contact:

Ronald Witteles, MD 650-498-4343

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: